Organon & Co | OGN - Loan Capital



Organon & Co reported $8.9B in Loan Capital for its fiscal quarter ending in June of 2025.


Loan Capital Change Date
Adcock Ingram Holdings ZAR 220.08M 18M Dec/2024
Bristol-Myers Squibb USD 44.47B 1.69B Jun/2025
Celltrion KRW 114.04B 8.35B Mar/2025
Cspc Pharmaceutical CNY 56.14M 10.18M Dec/2024
Dianthus Therapeutics USD 0 0 Dec/2024
Divis Laboratories Ltd 20M 0 Mar/2025
Gilead Sciences USD 22.14B 6M Jun/2025
Glaxosmithkline GBP 15.3B 667M Jun/2025
Kangmei Pharma CNY 84.24M 3.67M Jun/2025
Knight Therapeutics CAD 36.51M 2.04M Sep/2024
Laboratorios Farma EUR 101.36M 20.86M Jun/2025
Malin Corporation EUR 0 0 Dec/2024
Medical Developments International AUD 1.76M 150K Dec/2024
Merck USD 33.97B 484M Jun/2025
Neuren Pharmaceuticals AUD 0 0 Dec/2024
Novartis USD 24.06B 1.13B Jun/2025
Organigram Holdings CAD 52.8M 9.51M Jun/2025
Organon & Co USD 8.9B 36M Jun/2025
Pharma Mar EUR 37.57M 2.66M Jun/2025
Qiagen NV USD 884.85M 467.8M Jun/2025
Sartorius EUR 4.09B 112.3M Jun/2025
Sino Biopharmaceutical CNY 2.08B 915.48M Dec/2024
Tilray USD 316.63M 15.02M Nov/2024